Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

OBJECTIVE. To determine whether a non-platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. METHODS. Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tewari, Krishnansu S., Sill, Michael W., Birrer, Michael J., Penson, Richard T., Huang, Helen, Moore, David H., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286827/
https://www.ncbi.nlm.nih.gov/pubmed/36898292
http://dx.doi.org/10.1016/j.ygyno.2023.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286827/
https://www.ncbi.nlm.nih.gov/pubmed/36898292
http://dx.doi.org/10.1016/j.ygyno.2023.01.010

Ejemplares similares